{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-22-002286","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2022-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.292189+00:00","generated_at":"2026-06-22T22:29:22.937052+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexaria's DehydraTECH-CBD lowers blood pressure in 66-patient hypertension study","bullets":["Systolic BP reduced up to 5.60 mmHg (p<0.001) over 5 weeks vs. placebo; no serious adverse events.","BP reduction sustained for full study duration, exceeding cardiovascular risk reduction thresholds (4.6/2.2 mmHg).","Additive BP lowering observed in patients already on standard antihypertensive therapy.","Study used 225-450 mg/day DehydraTECH-CBD with zero serious adverse events and no liver enzyme changes.","Results support planned Phase Ib IND study with FDA; full results to be submitted for peer review."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-22-002286","json":"https://secwatch.observer/filing/0001640334-22-002286.json","markdown":"https://secwatch.observer/filing/0001640334-22-002286.md","text":"https://secwatch.observer/filing/0001640334-22-002286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033422002286/0001640334-22-002286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033422002286/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T22:29:22.937052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}